Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland.
Taru HallinenSanttu KiveläErkki SoiniVeli-Pekka HarjolaMari PesonenPublished in: ClinicoEconomics and outcomes research : CEOR (2023)
Empagliflozin is a cost-effective treatment for patients with HF in the Finnish health care setting.